Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies
Molecular cancer biomarkers help personalize treatment, predict oncologic outcomes, and identify patients who can benefit from specific targeted therapies. Colorectal cancer (CRC) is the third-most common cancer, with the liver being the most frequent visceral metastatic site. KRAS, NRAS, BRAF V600E...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1679 |
| _version_ | 1797612976591601664 |
|---|---|
| author | Yuliya Kitsel Timothy Cooke Vlasios Sotirchos Constantinos T. Sofocleous |
| author_facet | Yuliya Kitsel Timothy Cooke Vlasios Sotirchos Constantinos T. Sofocleous |
| author_sort | Yuliya Kitsel |
| collection | DOAJ |
| description | Molecular cancer biomarkers help personalize treatment, predict oncologic outcomes, and identify patients who can benefit from specific targeted therapies. Colorectal cancer (CRC) is the third-most common cancer, with the liver being the most frequent visceral metastatic site. KRAS, NRAS, BRAF V600E Mutations, DNA Mismatch Repair Deficiency/Microsatellite Instability Status, HER2 Amplification, and NTRK Fusions are NCCN approved and actionable molecular biomarkers for colorectal cancer. Additional biomarkers are also described and can be helpful in different image-guided hepatic directed therapies specifically for CRLM. For example, tumors maintaining the Ki-67 proliferation marker after thermal ablation have been particularly resilient to ablation. Ablation margin was also shown to be an important factor in predicting local recurrence, with a ≥10 mm minimal ablation margin being required to attain local tumor control, especially for patients with mutant KRAS CRLM. |
| first_indexed | 2024-03-11T06:49:25Z |
| format | Article |
| id | doaj.art-372305bbd0fb432cb121a9ac99d76ee9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:49:25Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-372305bbd0fb432cb121a9ac99d76ee92023-11-17T10:05:40ZengMDPI AGCancers2072-66942023-03-01156167910.3390/cancers15061679Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local TherapiesYuliya Kitsel0Timothy Cooke1Vlasios Sotirchos2Constantinos T. Sofocleous3Intervantional Oncology, IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAIntervantional Oncology, IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAIntervantional Oncology, IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAIntervantional Oncology, IR Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAMolecular cancer biomarkers help personalize treatment, predict oncologic outcomes, and identify patients who can benefit from specific targeted therapies. Colorectal cancer (CRC) is the third-most common cancer, with the liver being the most frequent visceral metastatic site. KRAS, NRAS, BRAF V600E Mutations, DNA Mismatch Repair Deficiency/Microsatellite Instability Status, HER2 Amplification, and NTRK Fusions are NCCN approved and actionable molecular biomarkers for colorectal cancer. Additional biomarkers are also described and can be helpful in different image-guided hepatic directed therapies specifically for CRLM. For example, tumors maintaining the Ki-67 proliferation marker after thermal ablation have been particularly resilient to ablation. Ablation margin was also shown to be an important factor in predicting local recurrence, with a ≥10 mm minimal ablation margin being required to attain local tumor control, especially for patients with mutant KRAS CRLM.https://www.mdpi.com/2072-6694/15/6/1679colorectal cancerliver metastasesbiomarkersgenomicsinterventional oncology |
| spellingShingle | Yuliya Kitsel Timothy Cooke Vlasios Sotirchos Constantinos T. Sofocleous Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies Cancers colorectal cancer liver metastases biomarkers genomics interventional oncology |
| title | Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies |
| title_full | Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies |
| title_fullStr | Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies |
| title_full_unstemmed | Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies |
| title_short | Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies |
| title_sort | colorectal cancer liver metastases genomics and biomarkers with focus on local therapies |
| topic | colorectal cancer liver metastases biomarkers genomics interventional oncology |
| url | https://www.mdpi.com/2072-6694/15/6/1679 |
| work_keys_str_mv | AT yuliyakitsel colorectalcancerlivermetastasesgenomicsandbiomarkerswithfocusonlocaltherapies AT timothycooke colorectalcancerlivermetastasesgenomicsandbiomarkerswithfocusonlocaltherapies AT vlasiossotirchos colorectalcancerlivermetastasesgenomicsandbiomarkerswithfocusonlocaltherapies AT constantinostsofocleous colorectalcancerlivermetastasesgenomicsandbiomarkerswithfocusonlocaltherapies |